Heart Attack News and Research

RSS

Cost-effective screening test for coronary artery disease

A simple, non-invasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

1 Oct 2009

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

In its continuous pursuit of quality cardiac care, Houston Northwest Medical Center was proudly recognized as the first accredited chest pain center in Houston and one of a handful in Texas to be named a Cycle III Chest Pain Center with PCI (percutaneous coronary intervention).

30 Sep 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Blood vessels in the retina may help predict risk of heart attack or stroke

For centuries eyes have been seen as windows to the soul. But medical researchers now believe the eyes may also offer vital clues to your risk of heart disease and stroke.

28 Sep 2009

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

25 Sep 2009

Dental plaque increases neutrophil activity in black males

Will neglecting to brush your teeth damage more than just your smile? Can failing to attack dental plaque increase your risk of heart damage?

25 Sep 2009

The Siebel Foundation to fund fellowships for Jacob School's top bioengineering graduate students

As breakthrough discoveries in bioengineering become more crucial to fundamental global issues, including health, food production and water supplies, UC San Diego's Jacobs School of Engineering's top ranked bioengineering department continues to be on the cutting edge of this field. The Siebel Foundation has recognized the Jacob School's pioneering efforts with a $2 million endowment to fund fellowships for some of its top bioengineering graduate students.

25 Sep 2009

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%,>

25 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

COMPARE trial results demonstrate higher efficacy of XIENCE V stent system

Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS).

24 Sep 2009

Guarding Hearts Alliance to protect quality care for patients suffering from heart disease

Organizations representing the vast majority of cardiologists around the country have joined forces today to preserve and protect the highest quality cardiac care available in America. Guarding Hearts Alliance is advocating to protect patient access to cardiac care in whatever Medicare changes or health care reform legislation is enacted.

24 Sep 2009

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.

24 Sep 2009

Cambridge Heart's modified Alternans technology to identify myocardial ischemia

Cambridge Heart, Inc. announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology.

24 Sep 2009

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009

Smoking bans result in consistent decline in heart attack rates: Study

A consistent decline in heart attack rates following the implementation of smoking bansStrongly enforced legislation to restrict smoking produces rapid and substantial reductions in community rates of heart attack, according to a meta-analysis published today in Circulation, the journal of the American Heart Association.

22 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009